Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of OPA-15406 Ointment in Healthy Japanese Men
NCT02334787Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jan 2015
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of difamilast in atopic dermatitis (AD) (4 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration (Cmax) of OPA-15406 in a Single Administration Period at 48 hours and Maximum Plasma Concentration (Cmax) of OPA-15406 in the Multiple Administration Period at Day 14. Started Jan 2015; status: completed.
02
Drugs
difamilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02334787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02334787.